三元生物(301206) - 2024 Q3 - 季度财报(更正)

Financial Performance - The company's operating revenue for Q3 2024 reached ¥138,076,442.87, representing a 19.16% increase year-over-year, and a total of ¥514,923,140.19 for the year-to-date, up 46.62% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2024 was ¥29,093,416.24, a significant increase of 248.18% year-over-year, with a year-to-date net profit of ¥81,007,173.94, up 94.39%[4] - Basic and diluted earnings per share for Q3 2024 were both ¥0.14, reflecting a 250.00% increase compared to the same period last year, with year-to-date earnings per share at ¥0.40, up 90.48%[4] - Total operating revenue for the current period reached ¥514,923,140.19, a significant increase of 46.5% compared to ¥351,192,635.35 in the previous period[27] - Operating profit for the current period was ¥85,493,929.39, up 90.5% from ¥44,871,999.14 in the previous period[28] - Net profit attributable to the parent company was ¥81,007,173.94, representing a 94.3% increase from ¥41,672,900.57 in the previous period[28] - Basic and diluted earnings per share increased to ¥0.40 from ¥0.21, reflecting a growth of 90.5%[28] - The company reported a tax expense of ¥4,736,208.37, compared to ¥3,377,080.39 in the previous period, indicating an increase of 39.9%[28] - The company recorded other income of ¥1,546,304.35, up from ¥821,692.01 in the previous period, marking an increase of 88.2%[27] Assets and Liabilities - The company's total assets at the end of Q3 2024 were ¥4,763,833,724.23, a slight decrease of 0.91% from the end of the previous year[4] - As of September 30, 2024, the total assets of the company amounted to ¥4,763,833,724.23, a slight decrease from ¥4,807,533,905.12 at the beginning of the period[25][26] - The company’s non-current assets totaled ¥1,407,629,556.93, compared to ¥4,485,720,051.15 at the beginning of the period, showing a significant decrease[26] - Total current liabilities were reported at ¥187,482,982.83, down from ¥224,197,013.02, indicating a reduction of about 16.4%[26] - The company’s retained earnings stood at ¥734,493,416.48, slightly down from ¥742,459,712.82, reflecting a decrease of about 1.1%[26] - The company’s total liabilities were reported at ¥239,671,475.10, down from ¥272,403,930.27, indicating a decrease of approximately 12%[26] Cash Flow - Cash flow from operating activities for the year-to-date was ¥6,970,913.77, down 68.23% year-over-year, primarily due to a reduction in bill settlements with suppliers[12] - Net cash flow from operating activities was ¥6,970,913.77, down 68.3% from ¥21,942,222.52 in the previous period[29] - Cash flow from investing activities generated a net inflow of ¥58,019,291.88, compared to a net outflow of ¥251,828,518.11 in the previous period[29] - Cash and cash equivalents at the end of the period totaled ¥80,824,019.10, down from ¥105,046,022.69 at the end of the previous period[30] - Cash and cash equivalents decreased to ¥86,800,655.34 from ¥108,808,330.03, reflecting a decline of approximately 20.2%[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,096, with the largest shareholder holding 46.23% of the shares[14] - The top 10 unrestricted shareholders hold a total of 56,000,000 shares, with the largest shareholder, Lü Xian, owning 12,852,000 shares, representing 6.35% of total shares[15] - Wang Shen, another significant shareholder, holds 5,265,910 shares, accounting for 2.60% of total shares[15] - The South China Xin Tai Private Fund Management Company, through its various funds, collectively holds 6,150,218 shares, which is approximately 3.04% of total shares[15] - The company has a total of 92,946,000 restricted shares held by Nie Zaijian, which will be released on August 10, 2025[19] - The total number of shares held by the top 10 unrestricted shareholders represents a significant portion of the company's equity, indicating strong institutional interest[15] - The company has seen a notable increase in the number of shares held by individual shareholders, with Li Dechun increasing his holdings to 2,880,000 shares[19] - The shareholder structure indicates a concentration of ownership, with the top three shareholders holding over 11% of the total shares[15] - The company has not reported any changes in the number of shares due to margin trading activities among the top shareholders[17] - The total number of shares held by Beijing Yi'an Capital Management Co., Ltd. is 1,731,779, representing 0.86% of total shares[17] - The company has a clear strategy for managing restricted shares, with specific release dates outlined for key executives[19] Governance and Strategy - The company completed the election of its fifth board of directors and supervisory board, ensuring continuity and stability in governance[21] - The company plans to expand its operational locations, with a new site at 101 Wutong 10th Road, Binbei District, Binzhou City[23] - The company has appointed Rongcheng Accounting Firm as its new external auditor for the 2024 fiscal year, following the termination of its previous auditor due to regulatory issues[24] - The board of directors held a meeting on October 30, 2024, to discuss future strategies[32] Accounting Standards and Reporting - The new accounting standards will be implemented starting from 2024, affecting the financial statements from the beginning of the year[31] - The company is preparing for the first-time execution of new accounting standards, which may impact financial reporting[31] - The third quarter report of Shandong Sanyuan Biotechnology Co., Ltd. has not been audited[32] - There are no specific performance summaries or user data provided in the documents[31][32] - No future outlook or performance guidance has been disclosed in the available content[31][32] - There is no mention of new product or technology development in the provided documents[31][32] - Market expansion or acquisition strategies are not detailed in the current reports[31][32] - The third quarter report does not include any financial metrics or performance indicators[31][32] - The documents do not provide any insights into new strategies being adopted by the company[31][32]